Sullivan & Cromwell is acting for longtime client Merck in its $3.9bn acquisition of US biotech company SpringWorks Therapeutics, which is being repped by Goodwin Procter.

Merck KGaA plans to acquire SpringWorks Therapeutics (NASDAQ:SWTX) for approximately $3.9 billion, aiming to enhance its ...

NEW YORK (AP) — U.S. stocks are drifting in mixed trading Tuesday as stronger-than-expected profits keep piling higher for ...

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 73 cents per share. The water and fuel pumping systems ...

HOUSTON (AP) — HOUSTON (AP) — Enterprise Products Partners L.P. (EPD) on Tuesday reported first-quarter profit of $1.39 billion. The Houston-based company said it had profit of 64 cents per share.

Current health news highlights include a dispute over EU drug pricing proposals, a U.S.-Mexico accord on screwworm management ...

The loans sat on banks' books for two-and-a-half years until the election of Donald Trump rapidly changed the company's fortunes. International Business Machines plans to invest $150 billion in the ...

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...

HOUSTON (AP) — HOUSTON (AP) — NOV Inc. (NOV) on Monday reported first-quarter earnings of $73 million. On a per-share basis, the Houston-based company said it had profit of 19 cents. The results fell ...

Health-care companies rose amid deal activity. Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology ...

Merck KGaA plans to acquire SpringWorks Therapeutics, a Connecticut-based specialist in biopharmaceuticals for severe rare diseases and cancer ...